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The ATP-sensitive potassium channel blocker glibenclamide
prevents renal ischemia/reperfusion injury in rats.
Background. Renal ischemia/reperfusion (I/R) is a com-
plex neutrophil-mediated syndrome. Adenosine-triphosphate
(ATP)-sensitive potassium (KATP) channels are involved in neu-
trophil migration in vivo. In the present study, we have investi-
gated the effects of glibenclamide, a KATP channel blocker, in
renal I/R injury in rats.
Methods. The left kidney of the rats was excised through a
flank incision and ischemia was performed in the contralateral
kidney by total interruption of renal artery flow for 45 minutes.
Renal perfusion was reestablished, and the kidney and lungs
were removed for analysis of vascular permeability, neutrophil
accumulation, and content of cytokines [tumor necrosis factor-
a (TNF-a), interleukin (IL)-1b , and IL-10] 4 and 24 hours later.
Renal function was assessed by measuring creatinine, Na+, and
K+ levels in the plasma and by determination of creatinine clear-
ance. Drugs were administered subcutaneously after the onset
of ischemia.
Results. Reperfusion of the ischemic kidney induced local
(kidney) and remote (lung) inflammatory injury and marked
renal dysfunction. Glibenclamide (20 mg/kg) significantly in-
hibited the reperfusion-associated increase in vascular perme-
ability, neutrophil accumulation, increase in TNF-a levels and
nuclear factor-jB (NF-jB) translocation. These inhibitory ef-
fects were noticed in the kidney and lungs. Moreover, gliben-
clamide markedly ameliorated the renal dysfunction at 4 and
24 hours.
Conclusion. Treatment with glibenclamide is associated with
inhibition of neutrophil recruitment and amelioration of renal
dysfunction following renal I/R. Glibenclamide may have a ther-
apeutic role in the treatment of renal I/R injury, such as after
renal transplantation.
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Renal ischemia/reperfusion (I/R) is a complex syn-
drome involving several mechanisms, including renal
vasoconstriction, tubular damage, and glomerular injury
[1]. It is an important cause of renal dysfunction in renal
transplantation and is associated with an increased rate of
acute and chronic rejection [2]. Although the restoration
of blood flow (i.e., reperfusion) is the treatment of choice
following acute ischemia of a vascular territory, reperfu-
sion of ischemic tissues can be accompanied by significant
injury to local and remote organs, such as the lung, and
systemic inflammatory events that may limit the benefi-
cial effects of blood flow restoration [3]. The mechanisms
proposed to explain the reperfusion-associated injury in-
clude anoxia, release of reactive oxygen species, such
as superoxide radical and hydrogen peroxide, recruit-
ment and activation of leukocytes and subsequent release
of mediators of the inflammatory process [3–5]. Neu-
trophil and tumor necrosis factor-a (TNF-a) are among
the cell types and inflammatory mediators, respectively,
thought to be of major relevance in the pathophysiology
of I/R injury [6–9]. It is believed that strategies limiting
reperfusion-induced influx of neutrophils and production
of TNF-a may be useful therapeutic adjuncts in the treat-
ment of acute ischemia [9].
The response of neutrophils to inflammatory media-
tors is preceded or accompanied by changes in mem-
brane potential [10–12], which increase the release of
Ca+2 from intracellular stores and stimulate the uptake
of extracellular Ca+2 [13]. These effects are thought to
be primary steps in neutrophil migration and have been
correlated with locomotion and chemotaxis [14, 15].
Glibenclamide has been shown to suppress neutrophil
migration and chemotaxis and affects plasma exuda-
tion during acute inflammatory responses, effects likely
related to its adenosine triphosphate (ATP)-sensitive
potassium (KATP) channel blocking activity [16]. In
the present study we have investigated the effects of
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glibenclamide in renal I/R injury in rats. For compari-
son, we have also evaluated the effects of the nonspecific
channel blocker tetraethylammonium (TEA) and of the
channel opener diazoxide.
METHODS
Animals
Male Wistar rats (200 to 220 g) obtained from the Bio-
science Unit of our Institution were housed in standard
conditions and had free access to commercial chow and
water. All procedures described here had prior approval
from the Institute Animal Ethics Committee.
I/R injury
Rats were anaesthetized with 185 mg/kg of ketamine
plus 16 mg/kg of xylazine (intramuscularly) and a left
nephrectomy was performed through a left flank inci-
sion. Renal ischemia required performing a right flank
incision and dissecting the right renal pedicle so as to ex-
pose the renal vessels. A thick cotton thread was passed
over the renal vascular pedicle to induce ischemia. Both
ends of the thread were exteriorized through the back of
the rat and tied tightly above a length of latex tubing on
the external side of the skin [17]. The renal pedicle was
released 45 minutes after occlusion by cutting the thread
and pulling it out followed by 4 or 24 hours of reperfu-
sion. Animals were allowed to recover from anesthesia
without further interventions. Throughout the anesthe-
sia, body temperature was kept at 36 to 38◦C by placing
the rats on a heating pad.
Glibenclamide (20 mg/kg) and a nonspecific potassium
channel blocker, TEA (40 mg/kg), were administered
through a single subcutaneous injection 40 minutes be-
fore the beginning reperfusion. In the groups submitted
to 24 hours of reperfusion, glibenclamide was also ad-
ministered 8 hours after reperfusion. The KATP channel
opener, diazoxide (30 mg/kg), was given intraperitoneally
40 minutes before reperfusion period. Dimethyl sulfox-
ide (DMSO) and ethanol were employed as vehicle for
administration of glibenclamide and diazoxide, respec-
tively, as previously described [16], and TEA was dis-
solved in a saline solution. The dose of glibenclamide
used here was based on previous work demonstrating that
this dose inhibited neutrophil migration and fluid leak-
age in carrageenan-induced pleurisy in rats [16]. Doses
of TEA and diazoxide were based on previous studies
[16, 18]. Drugs or vehicle were injected in a final volume
of 0.4 mL. Vehicle alone did not affect the parameters
analyzed when compared to animals not injected with
vehicle (data not shown). Sham-operated animals were
submitted to a left nephrectomy and were used as control
for the reperfusion-induced injury.
Evaluation of changes in vascular permeability
The extravasation of Evans blue dye into the kidney
and left lung tissue was used as an index of increased
vascular permeability [19]. Evans blue dye (20 mg/kg)
was administered intravenously (1 mL/kg) via a femoral
vein 5 minutes prior to reperfusion. After various times
(45 minutes, 4 hours, or 24 hours) after reperfusion, the
kidney and lungs were flushed with 20 mL of saline to
wash the intravascular Evans blue dye and were cut and
allowed to dry in a Petri dish for 24 hours at 37◦C. The
dry weight of the tissue was calculated and Evans blue
dye was extracted using 3 mL of formamide (24 hours
at room temperature). The amount of Evans blue dye
in the tissue was obtained by comparing the extracted
absorbance with that of a standard Evans blue dye curve
read at 620 nm in an automatic plate reader. Results are
presented as the amount of Evans blue dye per lg per
100 mg of tissue.
Myeloperoxidase (MPO) levels
The extent of neutrophil accumulation in the kidney
and right lung tissue was measured by assaying MPO ac-
tivity, as previously described [9]. A fragment of kidney
and right lung of the animals that had undergone I/R
(45 minutes, 4 hours, or 24 hours) injury was removed
and snap frozen in liquid nitrogen. Upon thawing, the tis-
sue (1 g of tissue per 19 mL of buffer) was homogenized
in pH 4.7 buffer [0.1 mol/L NaCl, 0.02 mol/L NaPO4,
and 0.015 mol/L sodium ethylenediaminetetraacetic acid
(EDTA)], centrifuged at 260 × g for 10 minutes and the
pellet underwent hypotonic lysis (15 mL of 0.2% NaCl so-
lution followed 39 seconds later by addition of an equal
volume of a solution containing 1.6% NaCl and 5% glu-
cose). After a further centrifugation, the pellet was then
resuspended in 0.05 mol/L of NaPO4 buffer (pH 5.4)
containing 0.5% hexadecyltrimethylammonium bromide
and rehomogenized. One milliliter aliquots of the sus-
pension were transferred into 1.5 mL Eppendorf tubes
followed by three freeze-thaw cycles using liquid nitro-
gen. These were then centrifuged for 15 minutes at 3000g
and the pellet discarded. Samples of lung were diluted
1:40 prior to the assay and samples of kidney were not di-
luted. MPO activity was assayed by measuring the change
in optical density at 450 nm using tetramethylbenzidine
(1.6 mmol/L) and H2O2 (0.5 mmol/L). Results were ex-
pressed as MPO relative units/100 mg of tissue. A MPO
relative unit represents the number of neutrophils ob-
tained by comparing the optical density of tissue super-
natant with that of rat peritoneal neutrophils processed
in the same way. To this end, neutrophils were collected
from the peritoneum of rats 8 to 12 hours after injec-
tion of 3 mL of 5% casein. A standard curve of neu-
trophil numbers versus optical density was obtained by
processing casein-elicited neutrophils (>95% purity by
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using this methodology), as above and assaying for MPO
activity. Under the conditions described above, the as-
say failed to detect the peroxidase activity derived from
monocytes/macrophages (data not shown).
Measurement of cytokine concentrations in kidney
and lungs
TNF-a, interleukin (IL)-1b , and IL-10 concentra-
tions were measured in kidney and lung of animals
using enzyme-linked immunosorbent assay (ELISA)
techniques previously described [20]. One hundred mil-
ligrams of kidney or lung of sham-operated and reper-
fused (4 or 24 hours) animals were homogenized in
1 mL of phosphate-buffered saline (PBS) (0.4 mmol/L
NaCl and 10 mmol/L NaPO4) containing antiproteases
[0.1 mmol/L phenylmethylsulfonyl fluoride (PMSF), 0.1
mmol/L benzethonium chloride, 10 mmol/L EDTA, and
20 kallikrein inhibitor unit (KI) aprotinin A] and 0.05%
Tween 20. The samples were then centrifuged for 10 min-
utes at 3000g and the supernatant immediately used for
ELISA assays at a 1:5 dilution in PBS. ELISA plates
(Nunc MaxiSorb) were coated with sheep antirat TNF-
a, IL-1b , or IL-10 polyclonal antibodies (1 to 2 lg/mL)
overnight. The plates were washed three times and then
blocked with 1% bovine serum albumin (BSA). After a
further wash, plates were incubated with samples or re-
combinant rat cytokine and incubated overnight. The bi-
otinylated polyclonal antibodies were used at a 1:1000
to 1:2000 dilution and the assays had a sensitivity of
16 pg/mL.
Measurement of mean arterial blood pressure
Mean arterial pressure (MAP) was measured by a
polyethylene catheter placed in the right femoral artery.
Blood pressure was measured during the 45 minutes of
ischemia followed by 4 hours of reperfusion. The pres-
sure signal was continuously monitored by a pressure
transducer (TSD 104A) connected to an amplifier MP100
System (Biopac Systems, Inc., Goleta, CA, USA) and a
computer-measuring program (Acqknowledge Software,
Goleta, CA, USA).
Determination of blood glucose levels
Since the blockade of KATP channels with gliben-
clamide is clinically used as an oral hypoglycemic ther-
apy, blood samples of animals were collected from vena
cava at the end of experiments (4 hours or 24 hours of
reperfusion) for assessment of glucose levels. For this, we
used a commercial kit (Bioclin, Belo Horizonte, Brazil).
Measurement of renal function
Creatinine clearance was assessed as an index of
glomerular filtration rate (GFR). Plasma samples were
prepared from blood obtained by vena cava puncture.
The concentrations of creatinine and urea were deter-
mined by colorimetric methods using commercially avail-
able kits (Bioclin) and were reported as mg/dL. Fractional
excretions of Na+ and K+ were calculated as the ratio be-
tween urinary excretion and the amount filtered (GFR ×
plasma concentration).
Histologic analysis
Sections of kidney were obtained from representative
animals in each of the treatment groups. The tissue was
fixed in 10% formalin, embedded in paraffin and 4 lm
thick section cuts. The sections were stained with hema-
toxylin and eosin and examined under a light microscope.
Preparation of nuclear extracts and band shift assay
Nuclear extracts were obtained from powdered kid-
ney and processed according to a previously published
method [21]. Tissue samples were obtained at 4 hours
after reperfusion. Nuclear extracts were allowed to in-
teract with the oligonucleotide containing nuclear factor-
jB (NF-jB) consensus binding site 5′-AGT TGA GGG
GAC TTT CCC AGC C-3′ labeled with [c-22P] ATP
using T4 polynucleotide kinase. After DNA binding,
complexes were resolved on nondenaturing 6% (wt/vol)
polyacrylamide gels and exposed at −80◦C.
Compounds
The following drugs were used: glibenclamide, TEA,
diazoxide, Evans blue dye (Sigma Chemical Co.), xy-
lazine (Bayer, Sa˜o Paulo, Brazil), ketamine (Agribrands
do Brasil Ltda, Sa˜o Paulo, Brazil), creatinine, glucose and
urea kits (Bioclin). ELISA kits for the detection of TNF-
a, IL-1b , and IL-10 were a kind gift of Dr, S.P. Poole,
National Institute for Biological Standards and Control,
Potters Bar, United Kingdom. All solutions were pre-
pared on the day of the experiment.
Statistical analysis
Results are shown as means ± SEM. Differences
were compared by using analysis of variance (ANOVA)
followed by Student-Newman-Keuls post hoc analysis.
Results with a P < 0.05 were considered significant.
RESULTS
Model of I/R injury
Initial experiments were designed to optimize the ki-
netics of renal injury following ischemia of the renal vas-
cular pedicle. An ischemic period of 45 minutes was used
in all experiments and the time of reperfusion varied from
0 to 24 hours. As seen in Figure 1A, an increase of in
vascular permeability in the kidney, as assessed by the
extravasation of Evans blue dye, was first significant at
4 hours after renal reperfusion. In addition to the re-
nal injury, there was a significant increase of vascular
1788 Pompermayer et al: Glibenclamide and reperfusion injury
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Fig. 1. Kinetics of the changes in vascular permeability (A and B) and in myeloperoxidase (MPO) contents (C and D) in the kidney and lungs
following ischemia (I) (45 minutes) and reperfusion (R) (45 minutes to 24 hours) of renal vascular pedicle. Evaluation of changes in vascular
permeability were assessed by Evans blue dye extravasation and neutrophil accumulation was assessed by measuring the tissue contents of MPO.
A dotted line across the bars was inserted to represent levels of Evans blue dye or MPO in sham-operated animals. Results are shown as lg Evans
blue dye per 100 mg of tissue or MPO, relative units per 100 mg of tissue and are the mean ± SEM of five to ten animals. ∗P < 0.05 when compared
to sham-operated animals.
permeability in the lung, an organ remote from the site of
injury (Fig. 1B). In the lung, the first significant increase
in vascular permeability was also detected 4 hours after
renal reperfusion.
MPO activity was measured in kidney and lung tissues
as a marker of neutrophil accumulation [22]. In the kid-
ney, the increase in MPO activity was first significant at
4 hours after renal reperfusion and increased further at
24 hours (Fig. 1C). In the lungs, neutrophils appeared
to be already trapped in the lungs in response to the is-
chemia (0 reperfusion time) and remained high in lung
tissues thereafter (Fig. 1D).
MAP was registered during renal I/R. There was no
change in MAP during the 45-minute ischemia. Unclamp-
ing of the renal pedicle produced a transient (5 minutes)
elevation of MAP (from 86 ± 6 to 108 ± 9 mm Hg)
(Fig. 2A).
Effects of the treatment with potassium channel blockers
on I/R injury
Glibenclamide significantly inhibited the reperfusion-
associated increase in vascular permeability in the kid-
ney at 4 and 24 hours. The drug also inhibited the
increase in vascular permeability in the lung after 4
hours of renal reperfusion. At 24 hours, the increase
in vascular permeability in the lung of glibenclamide-
treated animas had returned to baseline (Fig. 3A and
B). Similarly, treatment with glibenclamide effectively
prevented the accumulation of neutrophils in the kid-
ney of reperfused animals at 4 and 24 hours (Fig. 3C).
In contrast, the accumulation of neutrophils in the lungs
was not altered by the administration of the drug (Fig.
3D), which is consistent with the observation that neu-
trophils accumulated in the lungs during ischemia (see
Fig. 1) and the drug was administered after the onset of
ischemia.
We also tested the effects of the pretreatment with
the nonspecific potassium channel blocker, TEA, in an-
imals submitted to 4 hours of reperfusion. In the latter
experiments, the drug inhibited the increase in vascular
permeability by 70% and 60%, in the kidney and lungs,
respectively, but failed to affect neutrophil accumulation
in either organ (Table 1).
Effects of the treatment with potassium channel blockers
on the concentration of cytokines following I/R
The concentration of cytokines was measured in kid-
ney and lung tissues at 4 hours or 24 hours of renal
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Fig. 2. Mean arterial pressure (MAP) in rats submitted to renal is-
chemia (I) and reperfusion (R) in control groups (A) and glibenclamide
(20 mg/kg)-treated groups (B). The renal vascular pedicle was occluded
during 45 minutes following 4 hours of reperfusion. Results are shown
as mm Hg and are the mean ± SEM of four animals. Difference between
the groups was not statistically significant (P > 0.05).
reperfusion. Renal I/R induced a marked elevation in
the concentration of TNF-a in the kidney and lungs
(Fig. 4A and C). Treatment with glibenclamide sup-
pressed the reperfusion-induced TNF-a in the kidney
(inhibition of approximately 90%) and abolished the pro-
duction of the cytokine in the lungs at 4 hours of reper-
fusion (Fig. 4A and C). The drug also partially prevented
the increase in the concentration of TNF-a in the lungs
after 24 h of reperfusion (Fig. 4C).
There was also an increase in the concentration of
IL-1b at 4 hours, but not at 24 hours, of reperfusion
(Fig. 4B). Treatment with glibenclamide failed to affect
the reperfusion-induced increased in the concentrations
of IL-1b in the kidney (Fig. 4B). The concentration of this
cytokine in the lung was similar in sham-operated and
reperfused animals (data not shown). The concentration
of the anti-inflammatory cytokine IL-10 was greatly ele-
vated in the kidney at 4 hours, but not at 24 hours, after
reperfusion of the ischemic kidney (Fig. 4D). This cy-
tokine was not detectable in the lungs of sham-operated
and reperfused animals (data not shown). Treatment with
glibenclamide did not prevent the reperfusion-induced
increase in IL-10 concentrations in the kidney (Fig. 4D).
For comparison, we evaluated the effects of TEA on
the increases of TNF-a concentration induced by the is-
chemia followed by 4 hours of reperfusion. TEA had no
significant effect on the reperfusion-induced increase in
TNF-a concentrations in the kidney (I/R group 304 ±
66 pg/100 mg of tissue; treated with TEA 325 ± 45 pg/100
mg of tissue) (N = 4) or in the lungs (I/R group 53 ± 21
pg/100 mg of tissue; treated with TEA 12 ± 11 pg/100 mg
of tissue) (N = 4).
In contrast to its effects on inflammatory parameters,
glibenclamide had no significant effect on the transient
changes in MAP induced by the reperfusion process
(Fig. 2B).
Effects of glibenclamide on the changes of renal function
secondary to I/R injury
As glibenclamide modified inflammatory parameters
induced by the reperfusion process, next we evalu-
ated whether changes in inflammation were reflected by
changes in renal function. At 4 hours after reperfusion,
there was a minor increase in plasma creatinine concen-
trations in vehicle- but not glibenclamide-treated ani-
mals (sham-operated 1.3 ± 0.1 mg/dL; I/R 4 hours, 1.8 ±
0.2 mg/dL; and I/R + glibenclamide 1.5 ± 0.2 mg/dL)
(N = 5 in each group) (P < 0.05 for I/R versus sham).
There were no changes in plasma Na+ and K+ concen-
trations (data not shown).
A 24 hours, reperfusion of the ischemic kidney resulted
in a significant decrease in both urinary flow (Fig. 5A)
and in GFR (Fig. 5B). These functional changes were
prevented by treatment with glibenclamide (Fig. 5A and
B). Moreover, there were 39- and sevenfold increases in
fractional excretion of Na+ and K+, respectively (Fig. 5C
and D). Treatment with glibenclamide did not change
excretion of Na+ but significantly inhibited the excre-
tion of K+ (Fig. 5C and D). There was also a significantly
lesser increase in plasma concentration of creatinine (I/R
24 hours 2.4 ± 0.2 mg/dL and I/R + glibenclamide 1.8 ±
0.1 mg/dL) (N = 5 in each group) (P < 0.05).
Since glibenclamide is clinically used as an oral hypo-
glycemic therapy, we also measured blood glucose levels
at the end of 4 or 24 hours of renal reperfusion. Gliben-
clamide did not induce hypoglycemia in animals sub-
mitted to 4 hours of reperfusion (sham-operated 254 ±
19 md/dL; I/R 279 ± 29 mg/dL; and I/R + glibenclamide
228 ± 51 mg/dL) (N = 5 in each group). In groups of
animals submitted to 24 hours of renal reperfusion, the
levels of blood glucose were reduced in presence of
glibenclamide (I/R 228 ± 51 mg/dL and I/R + gliben-
clamide, 104 ± 23 mg/dL) (N = 5 in each group) (P <
0.05).
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Fig. 3. Effects of the treatment with glibenclamide on vascular permeability (A and B) and on myeloperoxidase (MPO) contents (C and D) in the
kidney and lung following ischemia(I) (45 minutes) and reperfusion (R) (4 or 24 hours) of renal vascular pedicle. Evaluation of changes in vascular
permeability were assessed by Evans blue dye extravasation and neutrophil accumulation was assessed by measuring the tissue contents of MPO.
Glibenclamide (20 mg/kg) was administered subcutaneously as described in the Methods section. Results are shown as lg Evans blue dye per 100
mg of tissue or MPO relative units per 100 mg of tissue and are the mean ± SEM of six to ten animals. ∗P < 0.05 when compared to sham-operated
animals; #P < 0.05 when compared to I/R animals.
Table 1. Effects of the treatment with a nonselective potassium
channel blocker, tetraethylammonium (TEA, 40mg/kg) on vascular
permeability and on neutrophil accumulation in the kidney and lung
following ischemia (45 min) and reperfusion (4 h) of renal vascular
pedicle
Evans blue MPO Relative
(lg/100 mg tissue) units/100 mg tissue
Kidney Lung Kidney Lung
Sham-operated 5 ± 0.70 8 ± 0.90 0.03 ± 0.01 2 ± 0.30
I/R 14 ± 1.50∗ 29 ± 5.70∗ 0.2 ± 0.04∗ 10 ± 1.90∗
I/R+TEA 4 ± 1.60# 12 ± 4.00∗# 0.1 ± 0.04∗ 12 ± 3.00∗
TEA (40 mg/kg) was administered subcutaneously 40 min prior to reperfusion
as described in the Methods section. Values are mean ± SEM of 5–10 animals.
∗P < 0.05 compared to sham-operated group, #P < 0.05 compared to ischemia
and reperfusion (I/R) group.
Effects of the treatment with glibenclamide on the
histologic analysis of renal tissue
Hematoxylin and eosin–stained histologic sections of
the kidneys undergoing reperfusion injury showed that
the changes were most prominent in the proximal tubules
(Fig. 6B). There was shedding of the cells lining the
tubules, sometimes complete, while other tubules showed
single cell necrosis with nuclear pyknosis and cytoplasmic
eosinophilia or vacuoles (Fig. 6B, insert). Overall the tis-
sue was congested with foci of interstitial hemorrhage.
The latter changes were more marked in the medulla. In-
filtrating neutrophils could be detected scattered in the
tissue. In contrast, sections of the glibenclamide-treated
kidneys showed architectural and cytologic preservation
of structure (Fig. 6C). Discreet vascular congestion was
observed. Overall the morphologic features in treated
animals were similar to those seen in control kidneys
(Fig. 6A).
Effects of the treatment with glibenclamide on
NF-jB translocation secondary to I/R injury
Translocation of the transcription factor NF-jB to
the nucleus in the kidney during 4 hours of reperfu-
sion was determined by electrophoretic mobility shift as-
says (EMSA) of kidney nuclear extracts. In the kidneys
of sham-operated rats, there was little evidence of NF-
jB translocation. I/R induced significant translocation of
NF-jB, as assessed by gel shift assays, and the translo-
cation was greatly prevented by glibenclamide treatment
(Fig. 7).
The specifity of the DNA-protein complex formed was
assayed by preincubating the nuclear extracts with 50-
fold molar excess of unlabeled oligonucleotides before
addition of the labeled oligonucleotide NF-jB. The DNA
protein interaction was completely blocked by competing
Pompermayer et al: Glibenclamide and reperfusion injury 1791
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Fig. 4. Effects of the treatment with glibenclamide on the concentrations of tumor necrosis factor-a (TNF-a) (A and C), interleukin (IL)-1b (B),
and IL-10 (D) in the kidney and lung following ischemia (I) (45 minutes) and reperfusion (R) (4 hours or 24 hours) of renal vascular pedicle. The
concentrations of TNF-a, IL-1b , or IL-10 were assessed in the kidney and lung by using specific enzyme-linked immunosorbent assay (ELISA).
Glibenclamide (GI) (20 mg/kg) was administered subcutaneously as described in the Methods section. Results are shown as pg of TNF-a, IL-1b ,
or IL-10 per 100 mg of tissue and are the mean ± SEM of six to 10 animals. Concentration of cytokines below the detection limit of the assay (16
pg/mL) was shown as < 16 pg/mL. ∗P < 0.05 when compared to sham-operated animals; #P < 0.05 when compared to I/R animals.
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Fig. 5. Effect of glibenclamide (GI) on uri-
nary volume (UF) (A), glomerular filtration
rate (GFR) (B), fractional excretion of Na+
FENa+) (C) and fractional excretion of K+
(FE K+) (D). Glibenclamide (20 mg/kg) was
administered subcutaneously as described in
the Methods section. Results are shown as
mean±SEM of seven animals. ∗P<0.05 when
compared to sham-operated animals; #P <
0.05 when compared to ischemia/reperfusion
(I/R) animals.
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A
B
C
Fig. 6. Kidney damage following ischemia (I) (45 minutes) and reper-
fusion (R) (4 hours) of renal vascular pedicle. Rats were sham-operated
(A), or submitted to ischemia and reperfusion (I/R) injury in the pres-
ence of vehicle (B) or glibenclamide (C). Glibenclamide (20 mg/kg) was
administered subcutaneously 40 min prior to reperfusion as described
in the Methods section. Kidneys were fixed and processed for histologic
analysis after hemoxytolin and eoasin staining [×20 in (A, B, and C)
and × 60 in the insert].
NF-κB
Free probe
Glib I/R Sham
Fig. 7. Translocation of the transcription factor nuclear factor-jB (NF-
jB) to the nucleus in the kidney during ischemia and reperfusion (I/R).
Kidneys of sham-operated rats, or submitted to I/R injury in the pres-
ence of vehicle or glibenclamide (Glib) were analyzed. Glibenclamide
(20 mg/kg) was administered subcutaneously 40 minutes prior to reper-
fusion as described in the Methods section. NF-jB was determined by
electrophoretic mobility shift assays (EMSA) of kidney nuclear extracts.
with the related oligonucleotide (NF-jB) but was not af-
fected by molar excess of unrelated oligonucleotide [acti-
vating protein-1 (AP-1)] confirming the specificity of the
interaction (data not shown).
Effects of the treatment with diazoxide on the I/R injury
Next, we investigated the effects of the ATP-sensitive
potassium channel opener diazoxide in the model of renal
I/R injury. Treatment with diazoxide had no significant ef-
fect on the reperfusion-induced changes in vascular per-
meability in kidney (sham-operated 5 ± 0.6 Evans blue
dye lg/100 mg of kidney; I/R 14 ± 1.5 lg; and I/R and
diazoxide 12 ± 0.4 lg) (N = 4) or lungs (sham-operated 8
± 0.9 lg Evans blue dye/100 mg of lung and I/R 29 ± 0.9
lg and 26 ± 8 lg) (N = 4). Similarly, diazoxide failed to
affect the reperfusion-induced increase in the concentra-
tion of cytokines in kidney and lungs (data not shown).
Nevertheless, the drug induced a further increase in the
accumulation of neutrophils in the lungs (sham-operated
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2 ± 0.3 neutrophils ×106/100 mg of lung; I/R 10 ± 1.9
neutrophils; and I/R and diazoxide 19 ± 1 neutrophils)
(N = 4) but not kidneys (sham-operated 0.03 ± 0.009 neu-
trophils ×106/100 mg of kidney; I/R 0.2 ± 0.4 neutrophils;
and I/R and diazoxide, 0.2 ± 0.1 neutrophils) (N = 4) of
reperfused animals. As expected by its potent vasodila-
tory effects, administration of diazoxide induced a 50%
fall in MAP shortly after its administration and persisted
at low levels to the end of experiment (data not shown).
DISCUSSION
Reperfusion of an ischemic vascular bed is accompa-
nied by local inflammatory injury that limits the potential
benefits of blood flow restoration. For example, renal is-
chemia followed by reperfusion results in severe injury
that may contribute to renal damage after organ trans-
plantation [23]. Thus, strategies that limit reperfusion-
associated renal damage may be useful during renal
transplantation. In addition, to renal damage, it is clear
that extensive I/R, such as that of the renal or intestinal
vascular beds, may be accompanied by remote (lung) and
systemic inflammation [9]. The latter may complicate the
reperfusion syndrome and contribute to overall lethality.
In this study, we evaluated whether the treatment with
glibenclamide prevented renal I/R inflammatory injury
and whether inhibition of inflammatory injury was ac-
companied by amelioration of renal dysfunction in rats.
Initial experiments were designed to investigate the
kinetics of the reperfusion-induced increase in vascular
permeability and neutrophil accumulation after ischemia
of the renal vascular pedicle for 45 minutes. The time of
ischemia employed here was based on previous studies
demonstrating it was optimal to cause injury [24, 25]. Our
results demonstrate that after 4 hours of renal reperfu-
sion there was a marked neutrophil accumulation and
increased vascular permeability in the kidney. In addi-
tion to causing local injury, 4 hours reperfusion of the
kidney was accompanied by accumulation of neutrophils
and increased vascular permeability in the lung, an or-
gan remote from the site of ischemia. These effects were
still present at 24 hours after reperfusion. In the lung, the
neutrophil accumulation was also detected during the is-
chemic period, possibly reflecting the inflammation in re-
sponse to the operation procedure necessary to remove
the contralateral kidney. The presence of neutrophils and
increased vascular permeability in local and remote or-
gans has also been observed after different models of I/R
[26–28].
We recently showed that the treatment of rats with
glibenclamide dose-dependently decreased the exu-
dation and neutrophil influx into the pleural cavity
induced by carrageenan, N-formyl-methionyl-leucyl-
phenylalanine and lipopolysaccharide [16]. Gliben-
clamide has been widely used as a KATP channel blocker
[16, 29, 30], although it may exert effects unrelated to
KATP channel blockage, such as thromboxane A2 recep-
tor antagonism [31] and Na+/K+-ATPase inhibition [32].
Although it cannot be ruled out that these other effects
may be relevant for the ability of glibenclamide to prevent
neutrophil migration, our previous study favored a more
relevant effect of glibenclamide on potassium channels.
Thus, both glibenclamide and a nonspecific KATP chan-
nel blocker prevented neutrophil influx, whereas minox-
idil, a KATP channel opener, worsened the inflammatory
response [16]. Treatment with glibenclamide, at a dose
(20 mg/kg) similar to that previously shown to decrease
the exudation and neutrophil influx into the pleural cav-
ity [16], significantly inhibited reperfusion-induced neu-
trophil accumulation and increased vascular permeability
in the kidney. Glibenclamide also inhibited the increase
in vascular permeability in the lung, whereas the neu-
trophil accumulation in this remote organ was unaffected
by glibenclamide. This is consistent with the results show-
ing that increased neutrophil accumulation in the lung
occurs during ischemia (see Fig. 1) and with the fact that
the drug was administered after the onset of ischemia.
Thus, it seems that both increase in vascular permeability
and neutrophil infiltration consequent to 4 or 24 hours of
reperfusion depends on the activation of KATP channels.
TEA, a nonselective potassium channel blocker, was also
effective to inhibit the increase in vascular permeability
in both kidney and lungs. Surprisingly, this drug had no ef-
fect on neutrophil accumulation. One possibility for the
absence of effect of TEA is the limited dose employed
here since doses of TEA greater than 40 mg/kg were not
tolerated by the animals and, thus, could not be used (data
not shown). Another explanation would be that inhibi-
tion of several potassium channel subtypes may confound
the results, as some subtypes may be pro- and other sub-
types may be anti-inflammatory. Overall, the present re-
sults are consistent with the notion [16] that inhibition
of KATP channels by glibenclamide is the mechanism by
which the drug prevents renal I/R injury.
It has been shown that TNF-a is a proinflammatory
cytokine capable of up-regulating its own expression and
that of other genes important for the inflammatory re-
sponse [33]. There was an increase in TNF-a concen-
trations in both kidney and lungs at 4 and 24 hours
after reperfusion of the ischemic kidney. These results are
in agreement with other studies showing the expression
and role for TNF-a in reperfusion-induced tissue injury
[9, 34–36]. Treatment with glibenclamide significantly in-
hibited the reperfusion-induced increase in TNF-a lev-
els in the kidney and lungs. As TNF-a may have a role
in the recruitment and activation of neutrophils in sites
of I/R injury [34], the ability of glibenclamide to inhibit
TNF-a production may account for its ability to prevent
reperfusion-induced neutrophil accumulation and organ
injury. On the other hand, we have previously shown that
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the accumulation of neutrophils is a prerequisite for the
production of TNF-a following intestinal I/R injury [9].
Whether the actions of glibenclamide are predominant
on TNF-a production or neutrophil influx remains to
be determined. Nevertheless, our studies showing that
neutrophil migration may be directly affected by gliben-
clamide suggest that neutrophils are a major cellular tar-
get for the action of the drug.
In addition to TNF-a, previous studies have shown that
the concentration of IL-1b is elevated and may have a
pathophysiologic role following I/R injury [37]. In IL-1
receptor knockout or in wild-type mice treated with
IL-1 receptor antagonist, the infiltration of polymor-
phonuclear leukocytes after renal I/R was attenuated
compared to control mice [38]. In our model, renal I/R in-
duced an increase in IL-1b levels in the kidney at 4 hours
after reperfusion, whereas there was no increase of the
cytokine in the lung. Treatment with glibenclamide had
no significant effects on the reperfusion-induced increase
of IL-1b in the kidney, suggesting that an effect on IL-
1b production does not underlie the inhibitory effects of
glibenclamide in our system.
Since IL-10 may be induced in reperfused tissue and
may modulate reaction to injury [39], we measured the
concentrations of this cytokine following renal I/R injury
and observed a significant elevation of IL-10 concentra-
tions in the kidney. Glibenclamide did not enhance or
inhibit the reperfusion-induced elevation in IL-10 con-
centrations. Thus, it is unlikely that an effect on IL-10 ex-
pression explains the modulatory effects of glibenclamide
in our system. Interestingly, whereas glibenclamide in-
hibited TNF-a production, this drug did not affect IL-10
production, suggesting that TNF-a is not an important
inducer of IL-10 in the system. Nevertheless, there was
a good correlation between the induction of IL-10 and
IL-1b in the kidney after I/R. We have previously demon-
strated that IL-1b is a major inducer of IL-10 during se-
vere intestinal I/R injury [40]. Whether IL-1b participates
in the cascade of events leading to IL-10 production dur-
ing renal I/R injury is not yet clarified.
NF-jB is a nuclear transcription factor that may con-
trol the expression of proinflammatory mediators, includ-
ing TNF-a [41]. In addition, proinflammatory mediators,
such as TNF-a, function by activating NF-jB in various
cell types. It is likely that these two systems amplify each
other in complex inflammatory syndromes, such as af-
ter I/R. Here, we observed that the reperfusion-induced
NF-jB expression in the kidney was inhibited by gliben-
clamide. The latter result is consistent with the ability of
glibenclamide to prevent the production of TNF-a fol-
lowing renal I/R. Thus, the prevention of NF-jB translo-
cation is part of the anti-inflammatory effects of gliben-
clamide in the system.
In addition to the inflammatory injury in the reper-
fused kidney, we also observed a marked renal dysfunc-
tion as assessed by a decrease in the GFR and urinary
flow. Glibenclamide, in parallel to its anti-inflammatory
effects, reversed the decrease in these renal parameters.
Thus, our results are indicative that the anti-inflammatory
effects of glibenclamide may improve the renal dysfunc-
tion consequent to renal I/R injury.
KATP channels are in various cell types other than
leukocytes. In the kidney, they are present in cells of prox-
imal tubule, thick ascending limb of Henle’s loop, and
cortical collecting duct [42]. It has been shown that a fall
in intracellular ATP concentration induces the opening
of KATP channels [43]. In the present study, we observed
an increase in the fractional excretion of K+ at 24 hours of
reperfusion. Since glibenclamide inhibited the increase in
the fractional excretion of K+, it was reasonable to sug-
gest that KATP channels in the kidney might be activated
during renal ischemia which, in turn, would increase the
renal excretion of K+. However, as there was no change
in the absolute renal K+ excretion (data not shown), the
observed changes in fractional K+ excretion may reflect
the changes in GFR rather than in K+ secretion. Frac-
tional excretion of Na+ was also increased at 24 hours
of reperfusion of ischemic kidney but was not affected
by glibenclamide. Since the increase in the excretion of
Na+ was not accompanied by an increase in the GFR, it
may be that renal ischemia followed by 24 hours reper-
fusion directly affected the tubular reabsorption of Na+,
probably without involvement of KATP channels.
Consistent with the expression of KATP on renal cells, a
protective effect of glibenclamide has also been observed
in experiments evaluating hypoxic renal injury ex vivo
[29, 43]. However, at least one study suggests that gliben-
clamide enhanced renal I/R injury in isolated perfused
rat kidney [30]. The reasons underlying the discrepancies
of these studies are not clear but could be related to the
different roles of KATP in various cell types in the kidney
[42]. Moreover, none of the studies have used neutrophils
or other leukocytes in their reperfusion system and neu-
trophils are thought to be major players of reperfusion
injury [6–9]. Thus, it appears that in the in vivo system
a role for glibenclamide on KATP of neutrophils may be
more relevant for the ability of the drug to prevent in-
flammatory injury and ameliorate renal dysfunction.
Insulin has been shown to have potential anti-
inflammatory activity by inhibiting the expression of the
proinflammatory intercellular adhesion molecule-1 [44].
Glibenclamide is widely used as a hypoglycemiant be-
cause of its ability to increase pancreas insulin secre-
tion by blockade of pancreatic KATP channels [45]. We
measured blood glucose levels at 4 and 24 hours of re-
nal reperfusion. Although levels of glucose were high
in rats submitted to renal I/R, these values were simi-
lar between the groups. High levels of glucose may be
due to the surgical stress (nephrectomy) carried out in
all groups. Similar values of blood glucose have been
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observed in rats submitted to nephrectomy [46]. After
24 hours of reperfusion, glibenclamide-treated animals
significantly decreased blood glucose levels to those seen
in nonmanipulated animals. It is unlikely that these
glucose-normalizing effects of glibenclamide may have
a role in our system but suggest the dose was sufficient
for an effective blockade of KATP channels in the present
study.
Although diazoxide induced a further increase in the
accumulation of neutrophils in the lungs, this drug failed
to affect the reperfusion-induced changes in vascular
permeability and reperfusion-induced increase in the
concentration of cytokines in kidney and lungs. One pos-
sibility is that the hypotensive effects of diazoxide may
prevent the adequate development of an inflammatory
response in the reperfused kidneys. Alternatively, a more
likely explanation is that the absence of an effect of di-
azoxide is that the model of renal I/R used here was
designed to produce a maximal inflammatory response.
Future studies in milder models of renal reperfusion in-
jury will help evaluating the latter possibility.
CONCLUSION
We demonstrated that glibenclamide is very effective
at inhibiting the local injury following I/R of renal vascu-
lar pedicle in rats. Inhibition of injury was accompanied
by amelioration of renal dysfunction. Altogether, our ex-
periments are in agreement with other studies showing
a role of KATP channels for neutrophil recruitment and
suggest that glibenclamide could have a therapeutic role
in the treatment of renal I/R injury, such as after renal
transplantation.
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